Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Panagiota Economopoulou(National and Kapodistrian University of Athens), Amanda Psyrri(National and Kapodistrian University of Athens), Nikolaos Oikonomopoulos(National and Kapodistrian University of Athens), Evangelos Giotakis(National and Kapodistrian University of Athens), Onoufrios Tsavaris(National and Kapodistrian University of Athens), Μaria Anastasiou(National and Kapodistrian University of Athens), Aris Spathis(National and Kapodistrian University of Athens), Μαρία Γκοτζαμανίδου(National and Kapodistrian University of Athens), Alexander Delides(National and Kapodistrian University of Athens), Efthymios Kyrodimos(National and Kapodistrian University of Athens), Nikolaos Spathas(Metropolitan Hospital), George Papaxoinis(St Savas Hospital), Ioannis Kotsantis(National and Kapodistrian University of Athens), Elena Vagia(Northwestern University), Eleni Gagari(Andreas Sygros Hospital), Niki Gavrielatou(National and Kapodistrian University of Athens)
Cited by 29
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
The Landscape of Targeted Therapies in TNBC
|Cancers|2020|448
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160